Nuwellis, Inc.

CHFS

US67113Y6032

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
4.58 ^USD	+8.27%		+20.21%	-77.47%

Jul. 09	Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference	CI
Jun. 06	Nuwellis Extends Pilot Program With Dialysis Services Provider DaVita	MT

Sunshine Heart, Inc. has Changed its Name to CHF Solutions, Inc

May 23, 2017 at 12:00 am EDT

On May 23, 2017, Sunshine Heart, Inc. changed its name to CHF Solutions, Inc.

Latest news about Nuwellis, Inc.

Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference	Jul. 09	CI
Nuwellis Extends Pilot Program With Dialysis Services Provider DaVita	Jun. 06	MT
Top Midday Gainers	May. 07	MT
Nuwellis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Transcript : Nuwellis, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (NUWE) NUWELLIS Reports Q1 Revenue $1.9M, vs. Street Est of $2M	May. 07	MT
Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	May. 02	CI
Maxim Downgrades Nuwellis to Hold	Apr. 29	MT
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	Apr. 09	CI
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days	Mar. 07	CI
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 06	CI
Transcript : Nuwellis, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M	Mar. 05	MT
Certain Warrants of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	Jan. 15	CI
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	Jan. 15	CI
Certain Common Stock of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	Jan. 15	CI
Nuwellis Receives FDA Approval for Specialized Catheter	Jan. 04	MT
Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter	Jan. 04	CI
Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients	Nov. 28	CI
Ladenburg Thalmann Downgrades Nuwellis to Neutral From Buy	Nov. 08	MT
Nuwellis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Transcript : Nuwellis, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (NUWE) NUWELLIS Reports Q3 Revenue $2.4M	Nov. 07	MT
Nuwellis, Inc. Announces Board of Directors Transition	Nov. 01	CI
Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption	23-10-10	CI

Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nuwellis, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.58

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NUWELLIS, INC.	-77.47%	2.18M
THERMO FISHER SCIENTIFIC	+4.64%	208B
DANAHER CORPORATION	+8.99%	182B
INTUITIVE SURGICAL, INC.	+29.83%	155B
BOSTON SCIENTIFIC CORPORATION	+35.17%	115B
SIEMENS HEALTHINEERS AG	+2.55%	66.52B
EDWARDS LIFESCIENCES CORPORATION	+15.06%	53.93B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.47%	46.26B
AGILENT TECHNOLOGIES, INC.	-2.14%	38.22B
GE HEALTHCARE TECHNOLOGIES INC.	+6.88%	36.6B

Other Advanced Medical Equipment & Technology

Nuwellis, Inc.

Equities

CHFS

US67113Y6032

Advanced Medical Equipment & Technology

Sunshine Heart, Inc. has Changed its Name to CHF Solutions, Inc

Latest news about Nuwellis, Inc.

Chart Nuwellis, Inc.

Company Profile

Income Statement Evolution

Ratings for Nuwellis, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology